On the HCPLive stroke page, resources on the topics of medical news and expert insight into CVA can be found. Content includes articles, interviews, videos, podcasts, and breaking news on stroke medicine, and more.
March 26th 2024
In a recent UK study, more than half of stroke survivors developed depression within 18 years.
Researchers Find Inadequate Levels of Thromboprophylaxis among Atrial Fibrillation Patients
November 20th 2013Analysis of health claims data indicates that physicians are underprescribing anticoagulant treatment in large numbers of patients with atrial fibrillation who are at high risk of stroke and low risk of bleeding.
Patients with Atrial Fibrillation Are at High Risk of Medication Noncompliance
November 18th 2013Study results presented at AHA 2013 show that nearly half of patients with nonvalvular atrial fibrillation (NVAF) are at high risk of discontinuing their medications. However, patients taking novel anticoagulants such as dabigatran or rivaroxaban were less likely to stop their medications.
Less Bleeding Associated with Novel Anticoagulants, but Use Not Recommended for all Patients
October 29th 2013Presentation at CHEST 2013 reviewed key considerations surrounding the treatment of pulmonary embolism and other venous thromboembolic events with the newer class of oral anticoagulant agents.
Rivaroxaban: A potential replacement for warfarin?
September 29th 2008Millions of people in the United States require chronic anticoagulation to prevent thromboembolism secondary to chronic atrial fibrillation (AF), pulmonary hypertension, mechanical valve replacements, and other prothrombotic conditions.
Antiplatelet and anticoagulant therapy in patients with atrial fibrillation
September 24th 2008We investigated 1209 patients with valvular and nonvalvular atrial fibrillation who were treated with standard anticoagulant therapy, the cyclooxygenase inhibitor triflusal, or combined therapy with triflusal and an anticoagulant. Compared with patients receiving standard anticoagulation treatment, the addition of antiplatelet therapy to reduced-intensity anticoagulation in patients stratified for risk of stroke significantly reduced the vascular event rate.
Cardiovascular morbidity in hypertensive patients with persistent atrial fibrillation
We conducted a substudy of the Rate Control Versus Electrical Cardioversion (RACE) study to evaluate cardiovascular morbidity, mortality, and the outcome of rate and rhythm control treatment in subjects with and without hypertension with persistent atrial fibrillation.